Nothing Special   »   [go: up one dir, main page]

AR113486A1 - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
AR113486A1
AR113486A1 ARP180103560A ARP180103560A AR113486A1 AR 113486 A1 AR113486 A1 AR 113486A1 AR P180103560 A ARP180103560 A AR P180103560A AR P180103560 A ARP180103560 A AR P180103560A AR 113486 A1 AR113486 A1 AR 113486A1
Authority
AR
Argentina
Prior art keywords
incretine
analogues
activity
receptors
incretin analogs
Prior art date
Application number
ARP180103560A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR113486A1 publication Critical patent/AR113486A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores de GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
ARP180103560A 2017-12-21 2018-12-05 Análogos de incretina y sus usos AR113486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
AR113486A1 true AR113486A1 (es) 2020-05-06

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103560A AR113486A1 (es) 2017-12-21 2018-12-05 Análogos de incretina y sus usos

Country Status (25)

Country Link
US (2) US11542313B2 (es)
EP (1) EP3727426A1 (es)
JP (2) JP6961838B2 (es)
KR (2) KR102444783B1 (es)
CN (1) CN111491658B (es)
AR (1) AR113486A1 (es)
AU (1) AU2018388962B2 (es)
BR (1) BR112020010244A2 (es)
CA (1) CA3084005C (es)
CL (1) CL2020001635A1 (es)
CO (1) CO2020006255A2 (es)
CR (1) CR20200255A (es)
DO (1) DOP2020000123A (es)
EA (1) EA202091290A1 (es)
EC (1) ECSP20032650A (es)
IL (1) IL275468A (es)
JO (1) JOP20200137A1 (es)
MA (1) MA51288A (es)
MX (2) MX2020006548A (es)
NZ (1) NZ765277A (es)
PE (1) PE20210162A1 (es)
PH (1) PH12020551025A1 (es)
SG (1) SG11202005606VA (es)
TW (3) TWI744579B (es)
WO (1) WO2019125938A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
KR20210091230A (ko) * 2018-11-12 2021-07-21 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
MX2022002115A (es) 2019-08-19 2022-03-17 Lilly Co Eli Metodos para preparar analogos de incretina.
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR121650A1 (es) * 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TWI837615B (zh) 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
AU2022280225A1 (en) 2021-05-26 2024-01-04 The United Bio-Technology (Hengqin) Co., Ltd. Multi-agonist and use thereof
WO2022268029A1 (zh) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
CN117915939A (zh) 2021-06-23 2024-04-19 伊莱利利公司 肠降血糖素类似物用于血糖控制和体重管理
EP4434536A1 (en) * 2021-11-19 2024-09-25 Medshine Discovery Inc. Stapled peptide and use thereof
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
CN117417411A (zh) * 2022-09-28 2024-01-19 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024213022A1 (zh) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013453A (es) * 2008-06-17 2011-01-21 Univ Indiana Res & Tech Corp Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad.
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
BR112012018104A2 (pt) * 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
EA035688B1 (ru) * 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
TWI670281B (zh) * 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI669309B (zh) * 2015-06-22 2019-08-21 美商美國禮來大藥廠 升糖素及ｇｌｐ－１共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805573RA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos

Also Published As

Publication number Publication date
CR20200255A (es) 2020-07-12
TWI744579B (zh) 2021-11-01
KR102622642B1 (ko) 2024-01-10
ECSP20032650A (es) 2020-07-31
DOP2020000123A (es) 2020-08-31
US11542313B2 (en) 2023-01-03
TW201938188A (zh) 2019-10-01
NZ765277A (en) 2024-08-30
PH12020551025A1 (en) 2021-09-06
IL275468A (en) 2020-08-31
MX2020006548A (es) 2020-09-14
US20230203121A1 (en) 2023-06-29
EA202091290A1 (ru) 2020-09-10
JP6961838B2 (ja) 2021-11-05
JP2021506955A (ja) 2021-02-22
MA51288A (fr) 2021-03-31
MX2024010201A (es) 2024-08-26
EP3727426A1 (en) 2020-10-28
CL2020001635A1 (es) 2020-10-16
CN111491658B (zh) 2024-04-26
JP2022033724A (ja) 2022-03-02
AU2018388962B2 (en) 2020-11-19
KR102444783B1 (ko) 2022-09-19
PE20210162A1 (es) 2021-01-26
TWI809515B (zh) 2023-07-21
BR112020010244A2 (pt) 2020-10-13
US20200331980A1 (en) 2020-10-22
KR20220133304A (ko) 2022-10-04
CA3084005C (en) 2024-01-02
WO2019125938A1 (en) 2019-06-27
CO2020006255A2 (es) 2020-05-29
KR20200088419A (ko) 2020-07-22
TW202202518A (zh) 2022-01-16
AU2018388962A1 (en) 2020-06-04
CA3084005A1 (en) 2019-06-27
TW202415675A (zh) 2024-04-16
CN111491658A (zh) 2020-08-04
JOP20200137A1 (ar) 2022-10-30
SG11202005606VA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
ECSP20032650A (es) Análogos de incretina y sus usos
ECSP20032306A (es) Análogos de incretina y sus usos
IL268702B (en) Use of a long-acting dual glp-1/glucagon receptor agonist for the treatment of non-alcoholic fatty liver disease
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
DOP2022000122A (es) Analogos de incretina y sus usos
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas
UY35622A (es) Moduladores de los receptores de estrógeno y sus usos